december 15, 2020
COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ — IO Biotech today announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. IO102 and IO103 are IO Biotech’s lead immuno-oncology candidates. Both compounds are based on...
LUNDBECKFONDEN UDDELER 57 MIO. KR. TIL DRISTIGE PROJEKTER DER KAN SKAFFE NY VIDEN INDEN FOR NEUROVIDENSKAB Bag projekterne står 29 forskere tilknyttet danske universiteter og hospitaler. De støttes af Lundbeckfondens forskningsprogram LF Experiment.   (De 29 forskere der har modtaget Lundbeckfondens LF Experiment bevilling 2020)   Det er let straks at affærdige en dristig ide,...
€5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares BYFAVO expected to be launched in the United States within the coming weeks This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 15...


Lundbeckfonden øger sit engagement i IO Biotech
12. januar 2021
Lundbeckfonden lancerer 2030-strategi med ambitiøse mål for både uddelings- og erhvervsaktiviteterne
22. december 2020
Lundbeckfonden uddeler 57 mio. kr. til dristige projekter
15. december 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge